Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab With or Without Branched-Chain Amino Acids in Unresectable Hepatocellular Carcinoma
ChiCTR2600127139Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Lenvatinib + Keytruda + BCAA with Lenvatinib + Keytruda (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600127139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127139.